Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CLL1 and CD38 Dual-Target CAR-T Cell · 1 trial · 1 indication
Proportion of subjects with DLT within 28 days after infusion of CLL1/CD38 dual-target CAR-T cell injection.
Proportion of subjects experiencing AE within 96 weeks after infusion of CLL1/CD38 dual-target CAR-T cell injection.
| Arm | Type | Description |
|---|---|---|
| Intervention（CLL1 and CD38 Dual-Target CAR-T Cell Injection） | EXPERIMENTAL | This study is a single-center open-label clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The enrolled subjects were patients with relapsed and refractory acute myeloid leukemia (r/r AML) . |
| Name | Type | Description |
|---|---|---|
| CLL1 and CD38 Dual-Target CAR-T Cell Injection | DRUG | This product is a lentiviral gene-modified autologous chimeric antigen receptor T-cell product that targets both CLL1 and CD38. |
Inclusion Criteria: 1. At the time of signing the informed consent, 18-70 years old (including the critical value); 2. Diagnosed with acute myeloid leukemia (except for APL) based on the World Health Organization (WHO) 2022 criteria and meeting the diagnostic criteria for relapsed/refractory AML (r...